πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 38 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12226429

Highly active compounds against COVID-19

Atea Pharmaceuticals, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084473

Ξ²-D-2β€²-deoxy-2β€²-Ξ±-fluoro-2β€²-Ξ²-C-substituted-2-modified-N6-substituted purine nucleotides f

Atea Pharmaceuticals, Inc. Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005139

Ophthalmic formulations and related methods

ETERNATEAR, INC. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12006340

Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

Atea Pharmaceuticals, Inc. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11975016

2β€²-substituted-N6-substituted purine nucleotides for RNA virus treatment

Atea Pharmaceuticals, Inc. Β· Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11964047

Ophthalmic formulations and related methods

ETERNATEAR, INC. Β· Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833160

Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseas

UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11813278

Highly active compounds against COVID-19

Atea Pharmaceuticals, Inc. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11738038

Highly active compounds against COVID-19

Atea Pharmaceuticals, Inc. Β· Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11707480

Highly active compounds against COVID-19

Atea Pharmaceuticals, Inc. Β· Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11701338

Use of gTso thal in manufacturing medicament for promotion of MS-275 to cross blood-brain

Northwest Institute of Plateau Biology, Chinese Academy of Sciences Β· Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11690860

Treatment of HCV infected patients with cirrhosis

Atea Pharmaceuticals, Inc. Β· Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679079

Ophthalmic formulations and related methods

ETERNATEAR, INC. Β· Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679078

Ophthalmic formulations and related methods

ETERNATEAR, INC. Β· Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11278493

Ophthalmic formulations providing durable ocular lubrication

ETERNATEAR, INC. Β· Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11110139

Application of anthocyanin extract in preparing pharmaceutical composition for preventing

Northwest Institute of Plateau Biology, Chinese Academy of Sciences Β· Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10946033

2β€²-substituted-N6-substituted purine nucleotides for RNA virus treatment

Atea Pharmaceuticals, Inc. Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10906928

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

Atea Pharmaceuticals, Inc. Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10894804

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

Atea Pharmaceuticals, Inc. Β· Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10888529

Vehicles for the transfection of miRNAs

UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10875885

Ξ²-d-2β€²-deoxy-2β€²-Ξ±-fluoro-2β€²-Ξ²-c-substituted-2-modified-n6-substituted purine nucleotides f

Atea Pharmaceuticals, Inc. Β· Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10874687

Highly active compounds against COVID-19

Atea Pharmaceuticals, Inc. Β· Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10870672

Ξ²-D-2β€²-deoxy-2β€²-Ξ±-fluoro-2β€²-Ξ²-C-substituted-2-modified-N6-substituted purine nucleotides f

Atea Pharmaceuticals, Inc. Β· Granted Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10870673

Ξ²-D-2β€²-deoxy-2β€²-Ξ±-fluoro-2β€²-Ξ²-C-substituted-2-modified-N6-substituted purine nucleotides f

Atea Pharmaceuticals, Inc. Β· Granted Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted